$273 Million is the total value of Iguana Healthcare Management, LLC's 75 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR SERIES TRUSTput | $12,916,000 | – | 250,000 | +100.0% | 4.73% | – | |
| New | ISHARES TRput | $11,063,000 | – | 100,000 | +100.0% | 4.05% | – | |
| New | SPDR S&P 500 ETF TRput | $10,276,000 | – | 50,000 | +100.0% | 3.76% | – | |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $9,064,000 | – | 85,000 | +100.0% | 3.32% | – |
| HCA | New | HCA HOLDINGS INC | $7,805,000 | – | 100,000 | +100.0% | 2.86% | – |
| MDT | New | MEDTRONIC PLC | $7,500,000 | – | 100,000 | +100.0% | 2.75% | – |
| PFE | New | PFIZER INC | $5,928,000 | – | 200,000 | +100.0% | 2.17% | – |
| LLY | New | LILLY ELI & CO | $5,401,000 | – | 75,000 | +100.0% | 1.98% | – |
| New | BIOGEN INCcall | $5,206,000 | – | 20,000 | +100.0% | 1.91% | – | |
| BSX | New | BOSTON SCIENTIFIC CORP | $3,762,000 | – | 200,000 | +100.0% | 1.38% | – |
| New | BRISTOL MYERS SQUIBB COcall | $3,194,000 | – | 50,000 | +100.0% | 1.17% | – | |
| New | INCYTE CORPcall | $2,899,000 | – | 40,000 | +100.0% | 1.06% | – | |
| New | REGENERON PHARMACEUTICALSput | $2,703,000 | – | 7,500 | +100.0% | 0.99% | – | |
| REGN | New | REGENERON PHARMACEUTICALS | $2,703,000 | – | 7,500 | +100.0% | 0.99% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $2,694,000 | – | 140,000 | +100.0% | 0.99% | – |
| New | MERCK & CO INC NEWput | $2,646,000 | – | 50,000 | +100.0% | 0.97% | – | |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $2,474,000 | – | 30,000 | +100.0% | 0.91% | – |
| KITE | New | KITE PHARMA INC | $2,296,000 | – | 50,000 | +100.0% | 0.84% | – |
| GKOS | New | GLAUKOS CORP | $2,108,000 | – | 125,000 | +100.0% | 0.77% | – |
| New | GW PHARMACEUTICALS PLCcall | $1,804,000 | – | 25,000 | +100.0% | 0.66% | – | |
| New | MEDIVATION INCcall | $1,609,000 | – | 35,000 | +100.0% | 0.59% | – | |
| New | ALNYLAM PHARMACEUTICALS INCput | $1,569,000 | – | 25,000 | +100.0% | 0.58% | – | |
| LDRH | New | LDR HLDG CORP | $1,529,000 | – | 60,000 | +100.0% | 0.56% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $1,390,000 | – | 50,000 | +100.0% | 0.51% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $1,307,000 | – | 150,000 | +100.0% | 0.48% | – |
| PETX | New | ARATANA THERAPEUTICS INC | $1,104,000 | – | 200,000 | +100.0% | 0.40% | – |
| TNET | New | TRINET GROUP INC | $1,076,000 | – | 75,000 | +100.0% | 0.39% | – |
| BLUE | New | BLUEBIRD BIO INC | $1,063,000 | – | 25,000 | +100.0% | 0.39% | – |
| New | SAREPTA THERAPEUTICS INCcall | $976,000 | – | 50,000 | +100.0% | 0.36% | – | |
| AERI | New | AERIE PHARMACEUTICALS INC | $912,000 | – | 75,000 | +100.0% | 0.33% | – |
| FLDM | New | FLUIDIGM CORP DEL | $807,000 | – | 100,000 | +100.0% | 0.30% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $778,000 | – | 75,000 | +100.0% | 0.28% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $638,000 | – | 75,000 | +100.0% | 0.23% | – |
| EXEL | New | EXELIXIS INC | $600,000 | – | 150,000 | +100.0% | 0.22% | – |
| GI | New | ENDOCHOICE HLDGS INC | $599,000 | – | 115,000 | +100.0% | 0.22% | – |
| FWP | New | FORWARD PHARMA A/Ssponsored adr | $510,000 | – | 30,000 | +100.0% | 0.19% | – |
| New | DERMIRA INCput | $414,000 | – | 20,000 | +100.0% | 0.15% | – | |
| New | ACCELERATE DIAGNOSTICS INCcall | $359,000 | – | 25,000 | +100.0% | 0.13% | – | |
| New | ARIAD PHARMACEUTICALS INCcall | $320,000 | – | 50,000 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.